Tilray Brands Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Tilray Brands (NASDAQ:TLRY)

Core Insights - Tilray Brands, Inc. is set to release its first-quarter earnings results on October 9, with analysts predicting a quarterly loss of 2 cents per share, compared to a loss of 1 cent per share in the same period last year [1] - The company anticipates quarterly revenue of $204.55 million, which represents an increase from $200.04 million a year earlier [1] Analyst Ratings - Jefferies analyst Kaumil Gajrawala has maintained a Buy rating and raised the price target from $1.5 to $2 as of August 25, 2025, with an accuracy rate of 50% [7] - Zelman & Assoc analyst Pablo Zuanic reiterated a Neutral rating on July 29, 2025, with an accuracy rate of 52% [7] - Piper Sandler analyst Michael Lavery maintained a Neutral rating but reduced the price target from $2 to $1 on April 9, 2025, with an accuracy rate of 65% [7] Recent Developments - On August 28, Tilray Brands' medical division expanded its portfolio in Germany by introducing three newly certified cannabis strains [2] - The company's shares fell by 2.5%, closing at $1.58 on a recent Monday [2]